Our June newsletter The last few weeks were packed with exciting advances in lung cancer. First, an “undruggable” mutation now has a targeted treatment option. On May 28, 2021, the global lung cancer community celebrated news that the US Food & Drug Administration (FDA) had granted accelerated approval for sotarasib as a second-line treatment for adults with KRAS G12C-mutated non-small cell lung cancer (NSCLC) with locally advanced or metastatic disease. This approval is meaningful for patients with KRAS lung cancer, as it marks a significant step forward to targeting a mutation that has eluded scientists for four decades. Read more about the significance of this approval in Dr. Amy Moore’s (Vice President, LUNGevity's Global Engagement and Patient Partnerships) blog post. Dr. Moore reminds us that this significant advancement is a testament to the continued momentum in the lung cancer treatment space. On the coattails of this approval was the annual American Society of Clinical Oncology (ASCO) meeting, which was held virtually for the second year in a row. The meeting was full of exciting research presentations and important updates about lung cancer. Juhi Kunde, LUNGevity’s science writer, discusses some of the major lung cancer findings and what it means for the lung cancer community in our ASCO Highlights blog post. Don’t miss out: COPE Summit 2021Now is your last chance to register for COPE Summit 2021. COPE Summit is a virtual conference designed by and for caregivers at all stages to get the tools and resources they need to navigate their loved one’s lung cancer care while connecting with others who share common experiences. You don’t need to take on caregiving alone. Join us June 25 – 26, 2021. COPE Summit is free to attend, but registration is required to reserve your spot. Subscribe to End Lung CancerAdd HOPE to your monthly subscriptions by becoming a LUNGevity Foundation monthly donor. The commitment of a monthly gift of any amount adds up to a major impact when we give as a community. Help fund lifesaving research and vital patient programs by subscribing today. 19,600 miles to eRACE Lung CancerThis May, more than 460 people from across the country (and around the world!) walked, ran, cycled, swam, skated, hiked, and rowed as part of eRACE Lung Cancer, LUNGevity’s 31-day activity challenge. Participants completed more than 19,600 miles and raised more than $150,000 to help raise funds and awareness for lung cancer. Thank you to all who participated! Missed the event but still want to raise funds and awareness for lung cancer? Registration for Breathe Deep TOGETHER is now open. Register and start fundraising today! |